|
1
|
Jemal A, Siegel R, Ward E, Murray T, Xu J,
Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin.
56:106–130. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nonomura N, Nishimura K, Okuyama A, Miki
T, Kishimoto T, Kiyohara H, Wakatsuki A, Fujioka H, Kuroda H,
Nakano E, et al: Prophylactic effect of pirarubicin (THP) on
postoperative recurrence of superficial bladder cancer in terms of
intravesical retention time. Hinyokika Kiyo. 47:315–319. 2001.(In
Japanese). PubMed/NCBI
|
|
3
|
Mansoor M, Ali S, Fasihuddin Q and Baloch
MU: Superficial bladder tumours: recurrence and progression. J Coll
Physicians Surg Pak. 21:157–160. 2011.PubMed/NCBI
|
|
4
|
Bulbul MA, Husseini N and Houjaij A:
Superficial bladder cancer epidemiology, diagnosis and management.
J Med Liban. 53:107–113. 2005.PubMed/NCBI
|
|
5
|
Jichlinski P and Leisinger HJ:
Fluorescence cystoscopy in the management of bladder cancer: a help
for the urologist! Urol Int. 74:97–101. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kawamura S, Fujioka T, Kubo T, Yoshida I
and Takata K: A course of pirarubicin vesical irrigation at thirty
mg effectively prevents post-TUR recurrence of superficial bladder
cancer. Gan To Kagaku Ryoho. 23:465–470. 1996.(In Japanese).
PubMed/NCBI
|
|
7
|
Babjuk M, Burger M, Zigeuner R, Shariat
SF, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A,
Palou Redorta J, et al: European Association of Urology: EAU
guidelines on non-muscle-invasive urothelial carcinoma of the
bladder: update 2013. Eur Urol. 64:639–653. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Joudi FN and Konety BR: Fluorescence
cystoscopy and bladder surveillance. Curr Opin Urol. 14:265–270.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Eissa S, Zohny SF, Shehata HH, Hegazy MG,
Salem AM and Esmat M: Urinary retinoic acid receptor-β2 gene
promoter methylation and hyaluronidase activity as noninvasive
tests for diagnosis of bladder cancer. Clin Biochem. 45:402–407.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Spiess PE and Grossman HB: Fluorescence
cystoscopy: is it ready for use in routine clinical practice? Curr
Opin Urol. 16:372–376. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hungerhuber E, Stepp H, Kriegmair M, Stief
C, Hofstetter A, Hartmann A, Knuechel R, Karl A, Tritschler S and
Zaak D: Seven years' experience with 5-aminolevulinic acid in
detection of transitional cell carcinoma of the bladder. Urology.
69:260–264. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Witjes JA and Douglass J: The role of
hexaminolevulinate fluorescence cystoscopy in bladder cancer. Nat
Clin Pract Urol. 4:542–549. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ferré A, Cordonnier C, Demailly M, Hakami
F, Sevestre H and Saint F: Bladder tumor targeting by
Hexvix(®) fluorescence: 4 years results after
prospective monocentric evaluation. Prog Urol. 23:195–202. 2013.(In
French). View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jain S and Kockelbergh RC: The role of
photodynamic diagnosis in the contemporary management of
superficial bladder cancer. BJU Int. 96:17–21. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Han J, Lin T, Xu K, Jiang C, Huang H, Yin
X, Xie W, Yao Y, Zhang C and Huang J: Improved detection of
nonmuscle invasive urothelial carcinoma of the bladder using
pirarubicin endoscopy: a prospective, single-center preliminary
study. J Endourol. 24:1801–1806. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hashimura T, Shirahase T, Inoue T,
Yamasaki T, Terada N, Ogura K, Arai Y, Hida S, Ueda T and Hinyokika
Kiyo: A randomized study of prophylactic intravesical instillation
of pirarubicin (THP) prior to transurethral resection of
superficial bladder cancer. Hinyokika Kiyo. 51:439–442. 2005.(In
Japanese). PubMed/NCBI
|
|
17
|
Shinohara N, Nonomura K, Tanaka M,
Nagamori S, Takakura F, Seki T, Koyanagi T, Togashi M and Maru A:
Prophylactic chemotherapy with anthracyclines (adriamycin,
epirubicin, and pirarubicin) for primary superficial bladder
cancer. The Hokkaido University Bladder Cancer Collaborative Group.
Cancer Chemother Pharmacol. 35:S41–S45. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hashimura T, Shirahase T, Inoue T,
Yamasaki T, Terada N, Ogura K, Arai Y, Hida S and Ueda T:
Diagnosing the location of carcinoma in situ (CIS) of the urinary
bladder using pirarubicin hydrochloride. Urol Int. 74:235–239.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mahjoubi M, Kattan J, Ghosn M, Droz JP,
Philippot I and Herait P: Phase II trial of pirarubicin in the
treatment of advanced bladder cancer. Invest New Drugs. 10:317–321.
1992. View Article : Google Scholar : PubMed/NCBI
|
